Intravitreal injections have surged with the rise of macular diseases. TSK Laboratory International is addressing this by introducing SteriJect ophthalmic needles.
SteriJect is approved for ophthalmic use and engineered for precise delivery of anti-VEGF medications.
TSK’s innovative Low Dead Space (LDS) technology minimises the space within the syringe-hub assembly, preventing air bubbles and reducing waste from sight-saving biologics. The hub geometry drives faster, cleaner flow, while the hard polymer construction ensures safe, secure attachment during injection. Partnering this advanced hub, TSK’s 33G and 34G profiles, with TSKiD technology, require less force for scleral penetration and intravitreal injection, minimising tissue damage, and discomfort. By prioritising patient safety and comfort, TSK is continually elevating the standard of ophthalmic care.
Contact: TSK Lab (AUS) 02 8077 9815 or visit shopaus.tsklab.com
